ARDELYX INCAA

ARDELYX INC

5.40EURR
−0.72−11.76%
At close at 21:13 GMT
EUR
No trades
See on Supercharts
Next report date
May 1
Report period
Q1 2025
EPS estimate
−0.10 EUR
Revenue estimate
‪72.01 M‬ EUR
Market capitalization
‪1.45 B‬EUR
−0.28EUR
‪−59.86 M‬EUR
‪112.76 M‬EUR
‪227.39 M‬
Beta (1Y)
0.30
Employees (FY)
267
Change (1Y)
+134 +100.75%
Revenue / Employee (1Y)
‪422.32 K‬EUR
Net income / Employee (1Y)
‪−224.18 K‬EUR

About Ardelyx, Inc.


CEO
Michael G. Raab
Headquarters
Waltham
Founded
2007
FIGI
BBG006QRY0T9
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
Performance
‪−90%‬
‪−60%‬
‪−30%‬
‪0%‬
‪30%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−30.00 M‬‬
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−30.00 M‬‬
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−30.00 M‬‬
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−35.00 M‬‬
‪0.00‬
‪‪35.00 M‬‬
‪‪70.00 M‬‬
‪‪105.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:May 1, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−0.15‬
‪−0.10‬
‪−0.05‬
‪0.00‬
‪0.05‬
Actual
Estimate

No news here

Looks like there's nothing to report right now

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 41X is 5.40 EUR — it has decreased by −11.76% in the past 24 hours. Watch ARDELYX INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ARDELYX INC stocks are traded under the ticker 41X.
41X stock has risen by 16.31% compared to the previous week, the month change is a 27.50% rise, over the last year ARDELYX INC has showed a −32.50% decrease.
We've gathered analysts' opinions on ARDELYX INC future price: according to them, 41X price has a max estimate of 14.30 EUR and a min estimate of 5.24 EUR. Watch 41X chart and read a more detailed ARDELYX INC stock forecast: see what analysts think of ARDELYX INC and suggest that you do with its stocks.
41X reached its all-time high on Feb 12, 2024 with the price of 9.42 EUR, and its all-time low was 3.04 EUR and was reached on Oct 13, 2023. View more price dynamics on 41X chart.
See other stocks reaching their highest and lowest prices.
41X stock is 20.64% volatile and has beta coefficient of 0.30. Track ARDELYX INC stock price on the chart and check out the list of the most volatile stocks — is ARDELYX INC there?
Today ARDELYX INC has the market capitalization of ‪1.45 B‬, it has decreased by −0.34% over the last week.
Yes, you can track ARDELYX INC financials in yearly and quarterly reports right on TradingView.
ARDELYX INC is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
41X earnings for the last quarter are 0.02 EUR per share, whereas the estimation was 0.00 EUR resulting in a 386.14% surprise. The estimated earnings for the next quarter are −0.10 EUR per share. See more details about ARDELYX INC earnings.
ARDELYX INC revenue for the last quarter amounts to ‪112.18 M‬ EUR, despite the estimated figure of ‪106.20 M‬ EUR. In the next quarter, revenue is expected to reach ‪72.01 M‬ EUR.
41X net income for the last quarter is ‪−726.60 K‬ EUR, while the quarter before that showed ‪−15.36 M‬ EUR of net income which accounts for 95.27% change. Track more ARDELYX INC financial stats to get the full picture.
No, 41X doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 20, 2025, the company has 267.00 employees. See our rating of the largest employees — is ARDELYX INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ARDELYX INC EBITDA is ‪−55.82 M‬ EUR, and current EBITDA margin is −49.80%. See more stats in ARDELYX INC financial statements.
Like other stocks, 41X shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARDELYX INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ARDELYX INC technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ARDELYX INC stock shows the neutral signal. See more of ARDELYX INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.